Pediatric rheumatology

Spectrum of clinical phenotypes associated with myositis-specific and myositis-associated antibodies in juvenile idiopathic inflammatory myositis: Our experience from North India

Semin Arthritis RheumPublished Retrospective cohort study

Authors' conclusion

Anti-NXP2 antibody is the most common MSA noted in our North Indian cohort of JIIM.

Study context

Population
Children with juvenile idiopathic inflammatory myositis, Pediatric Rheumatology Clinic of a tertiary care referral centre, Chandigarh, North India (1992 to 2024)MSA/MAA assayed in 113
Participants
173 children
Outcome
Incidence and clinical-phenotypic profile of MSA/MAA (16-antigen immunoblot)
Methodological detailssingle-centre, tertiary care referral centre
  • Single-centre
  • Tertiary care referral centre

Main finding

As reported in the abstract

Autoantibody positivity (MSA/MAA)
Any autoantibody positivity (82/113)
72.5%
MSA positive
70
MAA positive
12
Anti-NXP2 (most common)
24
Anti-MDA5
14
Anti-TIF-1γ
12
Anti-Mi 2
9

Observational data: associations, not effects.

Further findings

Phenotype of anti-NXP2-positive patients

Younger at onset, 3.15 years (1.2-11.88 years)
P = 0.015
Severe muscle weakness at onset
P = 0.04
Persistent calcinosis in follow-up
P = 0.004

Phenotype of anti-TIF1γ-positive patients

Persistent skin lesions during follow-up
P < 0.001

Phenotype of anti-MDA5 JDM (high incidence)

Arthritis
P = 0.001
Inverse Gottron papules
P = 0.003
Skin ulceration
P = 0.065
Oral ulcers
P = 0.012
ILD
P < 0.001

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Spectrum of clinical phenotypes associated with myositis-specific and myositis-associated antibodies in juvenile idiopathic inflammatory myositis: Our experience from North India. Semin Arthritis Rheum. Published 17 March 2026. doi:10.1016/j.semarthrit.2026.152972

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.